Erkan Yurtçu

Emerging cfDNA technologies in glioblastoma through fragmentomics and sonobiopsy

Glioblastoma (GBM) is difficult to monitor using liquid biopsy because the tumor-derived fraction of circulating cell-free DNA (cfDNA), i.e., circulating tumor DNA (ctDNA), is often very low in plasma and because spatial and temporal heterogeneity complicate single-variant tracki...